Skip to main content
Premium Trial:

Request an Annual Quote

Biofortuna to Use TriLink's CleanAmp dNTPs in PCR Kits

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – TriLink Biotechnologies today announced a licensing agreement for use of its CleanAmpl dNTPs with Biofortuna's freeze dried in vitro diagnostic PCR kits.

Terms of the deal were not disclosed.

In a statement, TriLink said that Biofortuna is developing unique HLA diagnostic kits that will address the transplantation, blood grouping, disease identification, and pharmacogenetic markets. The first product line will target the sequence-specific primer transplantation market.

Based in the UK, Biofortuna is an HLA molecular diagnostics firm.

The CleanAmp technology offers a "unique approach" to Hot Start activation in PCR by chemically modifying the essential DNA polymerase substrate, the dNTPs, Natasha Paul, TriLink scientific investigator, said in a statement. She added that CleanAmp dNTP can be used with different DNA polymerases and assay formats.

Biofortuna said that by using CleanAmp dNTPs as an alternative to standard dNTPs, it was able to improve the specificity of its genotyping assays. Mike Bunce, CEO of Biofortuna, added that the CleanAmp technology "allows us to create accurate, reproducible, and simple diagnostic kits, that greatly improve the quality of clinical testing and patient care."

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.